CARGO Therapeutics, Inc. Common Stock (CRGX) - Total Assets
Based on the latest financial reports, CARGO Therapeutics, Inc. Common Stock (CRGX) holds total assets worth $258.61 Million USD as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See CARGO Therapeutics, Inc. Common Stock (CRGX) net assets for net asset value and shareholders' equity analysis.
CARGO Therapeutics, Inc. Common Stock - Total Assets Trend (2021–2024)
This chart illustrates how CARGO Therapeutics, Inc. Common Stock's total assets have evolved over time, based on quarterly financial data.
CARGO Therapeutics, Inc. Common Stock - Asset Composition Analysis
Current Asset Composition (December 2024)
CARGO Therapeutics, Inc. Common Stock's total assets of $258.61 Million consist of 83.3% current assets and 16.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.6% |
| Accounts Receivable | $2.04 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how CARGO Therapeutics, Inc. Common Stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is CARGO Therapeutics, Inc. Common Stock worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: CARGO Therapeutics, Inc. Common Stock's current assets represent 83.3% of total assets in 2024, an increase from 4.1% in 2021.
- Cash Position: Cash and equivalents constituted 15.6% of total assets in 2024, up from 0.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
CARGO Therapeutics, Inc. Common Stock Competitors by Total Assets
Key competitors of CARGO Therapeutics, Inc. Common Stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
CARGO Therapeutics, Inc. Common Stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.37 | 16.96 | 0.09 |
| Quick Ratio | 12.37 | 16.96 | 0.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $237.70 Million | $421.67 Million | $-40.21 Million |
CARGO Therapeutics, Inc. Common Stock - Advanced Valuation Insights
This section examines the relationship between CARGO Therapeutics, Inc. Common Stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.52 |
| Asset Growth Rate (YoY) | -8.6% |
| Total Assets | $414.05 Million |
| Market Capitalization | $216.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values CARGO Therapeutics, Inc. Common Stock's assets below their book value (0.52x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: CARGO Therapeutics, Inc. Common Stock's assets decreased by 8.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for CARGO Therapeutics, Inc. Common Stock (2021–2024)
The table below shows the annual total assets of CARGO Therapeutics, Inc. Common Stock from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $414.05 Million | -8.60% |
| 2023-12-31 | $453.04 Million | +4322.88% |
| 2022-12-31 | $10.24 Million | +127.42% |
| 2021-12-31 | $4.50 Million | -- |
About CARGO Therapeutics, Inc. Common Stock
CARGO Therapeutics, Inc., a clinical-stage biotechnology company, focused on designing, engineering, and developing potentially curative cell therapies for cancer patients in the United States. The company develops CRG-023, a tri-specific CAR T product candidate which is in phase 1 that targets tumor cells with three B-cell malignancies; and allogeneic platform, a universal vector solution design… Read more